[{"orgOrder":0,"company":"ArrePath","sponsor":"PACE","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"AP-001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ArrePath","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ArrePath \/ PACE","highestDevelopmentStatusID":"4","companyTruncated":"ArrePath \/ PACE"}]

Find Clinical Drug Pipeline Developments & Deals for AP-001

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The proceeds will be used to develop a new class of antibiotics designed to address multidrug-resistant (MDR) infections, including AP-001 for the treatment of complicated urinary tract infections.

                          Brand Name : AP-001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 19, 2024

                          Lead Product(s) : AP-001

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : PACE

                          Deal Size : $1.2 million

                          Deal Type : Funding

                          blank